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ABSTRACT
Epstein-Barr virus (EBV) infects lymphocyte B and triggers latent phase in the 
host so that it causes nasopharyngeal carcinoma (NPC). Latent membraneprotein 
2A (LMP2A) epitope CTL-HLA-A24 is a target for recognition by cytotoxic T 
lymphocyte(CTL). The change in the epitope could influence the latency of 
particular EBV in the host due toits ability to evade immune surveillance 
mediated by CTL. The study aimed to determine thesequence variation of LMP2A 
epitope CTL-HLA-A24 gene from the peripheral blood samples and cytobrush 
of the NPC patients. Case-series study was conducted with total 16 cytobrush 
samples from NPC patients. DNA isolation, polymerasechain reaction (PCR) and 
gene sequencing were performed in this study. From cytobrush samples of NPC 
patients, it was found the changes of base sequence variation of LMP2A gene 
from GGC>GGA, CCA>CCC, TGC>TCC, GGT>GGC and TCT>ACT. CCA>CCC and 
TGC>TCC variations were found in epitope associated with HLA-A2 where there 
was a change of epitope sequence from TYGPVFMCL to TYGPVFMSL caused by 
missense mutation. The change of base sequence caused amino acid alteration 
from cysteine to serine. Whereas the variation of CCA>CCC did not change the 
sequence of amino acid proline so that the epitopewas unaffected. In epitope 
associated HLA-A2 (CLGGLLTMV), there was a change in base sequence from GGT 
to GGC, but there was no changes in amino acid and still as glycine. There were 
some new variations: in the upstream sequence of LMP2A from GGC>GGA which 
is silent mutation and the other variation is in downstream sequence of LMP2A 
from TCT>ACT which is missense mutation. Thesequence variations of LMP2A 
gene found in this research were GGC>GGA, CCA>CCC, TGC>TCC, GGT>GGC and 
TCT>ACT. In our research, we found another variation compared the previous 
research. The variation was in the upstream sequence of LMP2A from GGC>GGA 
which is silent mutation and the other variation is in the downstream sequence of 
LMP2A from TCT>ACT which is missense mutation.  
ABSTRAK
Epstein Barr Virus (EBV) menginfeksi limfosit B dan laten didalam tubuh host 
sehingga menyebabkan karsinoma nasofaring (KNF). Genlatent membrane 
protein 2a(Lmp2a) epitop CTL-HLA-A24 merupakan target cytotoxic T lymphocytes 
(CTL). Perubahan epitop tersebut dapat mempengaruhi latensi EBV dalam 
inang karena menghindari system imun yang dimediasi oleh CTL. Penelitian ini 
bertujuan untuk menentukan variasi sekuen gen LMP2A epitop CTL-HLA-A24 
dari sampel darah tepi dan cytobrush penderita KNF. Rancangan penelitian Case-
series digunakan pada penelitian ini. Sebanyak 16 sampel cytobrush penderita 
KNF dilakukan isolasi DNA, pemeriksaan polymerascechain reaction (PCR) yang 
dilanjutkan dengan sekuensing. Pada hasil sekuen sampel cytobrush penderita 
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KNF, ditemukan adanya perubahan variasi sekuen gen LMP2A yaitu perubahan 
susunan basa dari GGC>GGA, CCA>CCC, TGC>TCC, GGT>GGC dan TCT >ACT. Variasi 
CCA>CCC dan variasi TGC>TCC ditemukan pada epitope terkait HLA-A24 dimana 
terdapat perubahan epitope TYGPVFMCL menjadi TYGPVFMSL yang disebabkan 
oleh missense mutation, perubahan urutan basa TGC menjadi TCC dimana asam 
amino yang disandi berubah dari sistein menjadi serin. Sedangkan variasi CCA>CCC 
tidak mengubah susunan asam amino yang disandi yaitu prolin sehingga tidak 
merubah epitop. Pada epitop terkait HLA-A2 yaitu CLGGLLTMV, terjadi perubahan 
urutan basa GGT menjadi GGC, akan tetapi perubahan ini tidak merubah asam 
amino yang disandi yaitu sama-sama menyandi asam amino glisin. Variasi baru 
ditemukan pada bagian upstream sekuen LMP2A yaitu GGC>GGA yang berupa 
silentmutation dan pada bagian downstream sekuen LMP2A yaitu TCT>ACT yang 
berupa missense mutation. Variasi sekuen gen LMP2A yang ditemukan adalah 
perubahan susunan basa dari GGC>GGA, CCA>CCC, TGC>TCC, GGT>GGC dan 
TCT>ACT. Dalam penelitian ini ditemukan variasi yang berbeda dengan penelitian 
sebelumnya yaitu pada bagian upstream sekuen LMP2A yaitu GGC>GGA yang 
berupa silentmutation dan pada bagian downstream sekuen LMP2A yaitu TCT>ACT 
yang berupa missense mutation. 
INTRODUCTION
Nasopharyngeal carcinoma (NPC) 
is an epithelial tumor located on the 
surface of the nasopharynx. NPC is a 
malignant tumor that mostlyinvades the 
head and neck. This carcinoma is rare in 
some countries in the world, especially 
in Europe and North America.1 However, 
manyare distributed in a particular 
ethnic and geographic area.2 The 
incidence of NPC is high in some areas 
of southern China, especially in Canton, 
Guangzhou that is 30-80/100,000 per 
year.3 NPC cases in Indonesia continue to 
increase over time. In Yogyakarta Special 
Region, the incidence of NPC is increased 
each year.4,5
Epstein-Barr virus (EBV) is proven 
to be responsible for the occurrence 
of NPC andcommonly associated 
withthe progression of the disease.2,6 
EBV is the main virus that caused 
mononucleosis infection, mainly found 
in nasopharyngeal tumour cells but not 
all the lymphocytes.2 Besides virus, there 
are other risk factors that could causeNPC 
such as ethnic, smoking, genetic and 
gender. EBV infects nearly 95% percent 
of world population and not only caused 
cancer disesases.7
EBV enters the human body by saliva 
through oropharynx mucosa and infects 
B cell residing in the submucosa by 
CD21-Gp350 bond between them. After 
that, EBV enters B cell’s cytoplasm and 
dissembles its body and let its genetic 
material to enter the nucleus. EBV can 
undergo a latent phase after infecting 
B cell and reside in the body of the host 
for all the time.6 EBV-infected B cells will 
produce latent antigens such as Latent 
Membrane Protein (LMP)1 and LMP2 
(LMP2A and LMP2B). LMP1 is detected 
approximately 65 and 35% in NPC 
patients in mRNA and protein levels, 
whereas LMP2A is found in more than 
95% of NPC samples in mRNA levels and 
50% in protein level, respectively.8
LMP2A is responsible for the latent 
phase of EBV-infected B cell by inhibiting 
or disrupting B cell’s signal transduction, 
keeping the virus in the latent phase/
persistence.6,8-11 It is immunogenic and 
acts as themain target of cytotoxic T 
lymphocytes (CTLs) in NPC.CTLdetects the 
virus by recognizing antigen presented 
by class I MHC (major histocompatibility 
complex) in surface of target cell. EBV-
infected cells will express latent antigens 
and showed them in the surface in the 
form of epitope-class I HLA that may 
cause T cell response (CTLs). Stevens et 
al.12 have identified so far seven epitope 
targets by CTL in LMP2A, whereas Khana 
et al.9 reported that CTL recognizes 
recombinant LMP2A epitope associated 
with HLA-A2 in tumour cells having 
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disturbance in protein TAP regulation, 
so that this virus isolate evading immune 
response through the change in amino 
acid chain in CTL’s epitope.13
Epitope part of LMP2A associated 
with CTL-HLA A24 gene has TYGPVFMCL 
amino acids arrangement. Previous study 
found that a change in that region in 
NPC patients could affect the recognition 
site of the epitope so that CTL could not 
recognize the new epitope, thus allowing 
EBV to avoid the immune surveillance of 
CTLs.9 HLA–A24, HLA-A11 dan HLA-A2 
type are found in NPC patients resides 
in south east Asia and caucasian.14Prior 
study found that out of nine people 
(healthy or infected with EBV), HLA-A24 
showed the highest number, followed 
by HLA-A11 and HLA-A2. Native 
Indonesians with HLA-A24 have high 
probabilities of NPC.15
NPC cases in Indonesia continue 
to increase due to most patients 
diagnosed at the late stage, so treatment 
failureoccasionally occurs. To minimize 
the number of cases and treatement 
failure, early screening needs to be 
undertaken. Never theless, the study 
of genetic profile in patients with NPC 
remainsscarce. Therefore, we aimedto 
find LMP2A-CTL epitope-HLA A24 gene 
in the peripheral blood and cytobrush of 
NPC patients, and also peripheral blood of 
healthy people. In addition, the sequence 
variation of LMP2A-CTL epitope-HLA 
A24 gene from those samples will be 
determined.
MATERIALS AND METHODS
Design and samples
This is a Case Series design towards 
the occurrence of sequence variation of 
Lmp2a-CTL epitope-HLA A24 gene from 
the samples of cytobrush NPC patients. 
Peripheral blood and cytobrushwere 
obtained from the NPC patients at ear-
nose-throat (ENT) polyclinic in Dr. Sardjito 
General Hospital,  Yogyakarta, Indonesia.
Procedure
DNA isolation and PCR were 
performedat Laboratory of Molecular 
Biology,  Faculty  of Medicine, Public 
Health, and Nursing, Universitas Gadjah 
Mada, Yogyakarta and sequencing was 
done at Genetika Science Indonesia – 
Laboratorium 1st Base.
Method used in DNA isolation is 
Booms method using kit. NucliSENS® Lysis 
Buffer, NucliSENS® automated isolation 
reagent (wash buffer, eluent buffer, 
silica), aseton, etanol 70%, H2O steril, 
HPLC water, platinum taq DNA 
polymerase (include buffer, MgCl2), 10 
mM dNTP mix, Ultra Pure DNAse/RNAse, 
trisma base, 100bp DNA ladder (marker), 
lyophilized primer 100 nmol gen lmp2a, 
ddNTP set Bio Chemika, GF-1 PCR Clean 
Up Kit, 100bp DNA Ladder, loading 
buffer, agarose gel electrophoresis, TAE 
buffer, ethidium bromide.
PCR was performed with 1 µL DNA in 
a 24 µLtotal reaction mixture containing 
primer 10pmol 1µL for each forward and 
reverse, buffer 10x 2.5µL, MgCl2 50nm 
1.5µL, dNTP mix 10nm 0.2µL, Taq DNA 
Polymerase 0.1 µL.The primer used for 
LMP2A was5’-CAT TCT TGC TAT CCT GAC 
CG 3’(forward primer) and5’-CTC CTC ACT 
TTC CAG TGT AAG G-3’(reverse primer).9 
The amplification protocol was one cycle 
at 95°C for 5min, followed by 35 cycles of 
PCR with denaturation temperature 94°C 
for 1min, annealing temperature 58°C 
for 50 sec, extension temperature 72°C 
for one min, final extension 72°C for 5 
min, 4°C. Result product has 324 bp. PCR 
product then under wentelectrophoresis 
using 2.5% agarose gel with ethidium 
bromide to see the LMP2A gene band.
ThePCR reaction product was 
extracted and purified. Sequencing 
was performed to see variation of 
base sequence coding LMP2A epitope 
associated withCTL-HLA A24. Sequencing 
consists of purification, cycle sequencing 
and precipitation.
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Statistical analysis
The analysis of the LMP2A epitope 
CTL-HLA A24 gene and its variation 
wasperformedby descriptive analysis. 
RESULTS
Sixty-four subjects were involved 
in the study and divided into 32 NPC 
patients and 32 healthy individuals 
(TABLE 1). Most of NPC patients were in 
the late stage (Stage IV).
TABLE 1. Characteristics of subjects
Characteristics NPC patients(%)(n = 32)
Control (%)
(n = 32)
Sex
•	 Male 21 (65.6) 21 (65.6)
•	 Female 11 (34.4) 11 (34.4)
Age (year) 50.9 ± 13.9 49.0 ± 14.9
StageTNM
•	 I 1 (3.1)
•	 II 1 (3.1)
•	 III 4 (12.5)
•	 IV 26 (81.3)
Amplification LMP2Agene from 
peripheral blood sample of NPC 
patient
Thirty-two peripheral blood samples 
of NPC patients are amplified according 
to the prior PCR optimization. DNA 
band emerged in this experiment only 
in positive control and there was no 
emerging band in peripheral blood 
samples of NPC patients (FIGURE 1A). 
The amplified of actin gene acted as 
a control (FIGURE 1B). It showed that 
none or very few EBVs was taken in 
the patients’ peripheral blood samples. 
Some of the samples were not good, 
for the example in sample 10-106, actin 
was slightly amplified, shown that the 
quality of this DNA sample was not good 
comparing to other samples.
FIGURE 1. (A) PCR Electrophoresis for LMP2A on peripheral blood 
samples NPC, agarose gel 2%. M is marker 100bp Vivantis, 
K+ is positive control, number on the upside panel is samples 
number (1-15). On the right panel is product basepair 320bp, 
showing by arrow. There is no DNA fragment amplification, 
(B) PCR of actin gene as acontrol gene, there is fragment 
amplification in all samples. Showing by headarrow is one 
of the sample which is too faint DNA amplification
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Amplification LMP2Agene from 
cytobrush sample of NPC patient
Thirty-two cytobrush samples of the 
NPC patients are amplified according 
the to the prior PCR optimization. In this 
test, DNA band emerged only in positive 
control and most cytobrush samples with 
variable thickness of the band (FIGURE 
2A). For sample number 11-01B, the gene 
is not amplified, while in PCR actin it is 
amplified. It is proof that there was not 
enough even none of EBVs in sample 11-
01B so that there was no amplification of 
LMP2A gene. Likewise, in sample 11-11B, 
11-13B, 11-14B and 11-15B, there were 
no amplified LMP2A gene whereas actin 
gene (control) were amplified (FIGURE 
2B).
FIGURE 2. (A) PCR Electrophoresis for LMP2A on cytobrush samples NPC, 
agarose gel 2%. M is marker 100bp Vivantis, K+ is    positive 
control, number on the upside panel is samples number (1-
12). On the right panel is product basepair 320bp, showing 
by arrow. DNA fragment amplification show in most of 
cytobrush samples. Showing by arrow is sample number 6 
is no amplification; (B)PCR of actin gene as acontrol gene, 
there is fragment amplification in all samples. Showing by 
headarrow is   sample number 6 (11-01).
Amplification LMP2Agene from 
peripheral blood sample of control 
Thirty-two peripheral blood samples 
of control are amplified according to the 
previous PCR optimization. DNA band 
emerged only in positive control and it 
was not found any DNA band in sample 
groups (FIGURE 3A). Control gene actin 
was amplified in all samples (FIGURE 
3B). It wasproof that the quality of 
control DNAs were still good and there 
was no LMP2A gene in peripheral blood 
samples of the controls.
FIGURE 3. (A) PCR Electrophoresis for LMP2A on peripheral blood control 
group, agarose gel 2%. M is marker 100bp Vivantis, K+ is 
positive control, number on the upside panel is samples 
number (1-15). On the right panel is product basepair 320bp, 
showing by arrow. There is no DNA fragment amplification; 
(B) PCR of actin gene as acontrol gene, there is fragment 
amplification in all samples. 
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Sequence variation of LMP2Agene 
from cytobrush samples
Twenty six of 32 cytobrush samples 
were successfully amplified. Only 16 
of 26 successfully amplified samples 
that could be clearly analyzed using 
sequencing. Based on sequencing test, 
there was a change in gene sequence 
compared to wildtype (Gen Bank AJ 
507799.2). It was also found another 
epitope besides CTL-HLA-A24, named 
CTL-HLA-A2, so that the results need to 
be analyzed thoroughly.
 
 
FIGURE 4. The result of variation sequence. Arrow 1 : changes from GGC to 
GGA; Arrow 2 : changes from CCA  to CCC; Arrow 3 : changes from 
TGC to TCC; Arrow 4 : changes from  GGT to GGC; andArrow 5 : 
changes from  TCT to ACT
Distribution Sequence variation of 
LMP2Agene from cytobrush samples
Based on analysis, it was found 
five different variations in each sample 
which undergoing reanalysis to see the 
distribution between those variations 
in all samples (TABLE 2). The variations 
are: Type I: TCT>ACT (change in one 
nucleotide), Type II: GGC>GGA, CCA>CCC, 
TGC>TCC, GGT>GGC(change in four 
nucleotides) and Type III: GGC>GGA, 
CCA>CCC,TGC>TCC, GGT>GGC,TCT>ACT 
(change in five nucleotides).It was found, 
Type I with a change in one nucleotide as 
many as 37.5%, Type II with four changes 
of nucleotide as many as eight samples 
(50%) and Type III with five changes of 
nucleotide as many as 12.5% from all 
samples.
1 2 3 4
    
5
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TABLE 2. Distribution Sequence variation of LMP2A gene from cytobrush samples
Type n (%) Sequence variation
Type I 6 (37.5) TCT>ACT   
Type II 8 (50) GGC>GGA, CCA>CCC, TGC>TCC, GGT>GGC
Type III 2 (12.5) GGC>GGA, CCA>CCC, TGC>TCC, GGT>GGC, TCT>ACT
Total 16 (100)
The relationship between sequence 
variation of LMP2Agene and 
tumorstage
From the results above, it was 
showedthe relationship between 
sequence variation of LMP2A gene and 
tumorstage (TABLE 3). In type I, it was 
found the same presentation between 
stage 4a and 4c which was 50%. In Type 
II, the presentation differed between 
stage3, 4a and 4b whereas the highest 
presentation was in stage4b (62.5%). 
In Type III, it was also found the same 
presentation between stage 4a and 4b 
which was 50% each. Compared to Type 
II and Type III, only in Type I (the change 
of nucleotide TCT>ACT) stage 4c could be 
found. 
TABLE 3. The relationship between sequence variation of LMP2A gene and tumourstage
Sequence variation
Stage [n (%)]
1 2 3 4a 4b 4c
Type I (TCT>ACT)
(n = 6)
- - - - 3(50) 3(50)
Type II (GGC>GGA; CCA>CCC; TGC>TCC; 
GGT>GGC)
(n=8)
- - 1(12.5) 2(25) 5(62.5) -
Type III (GGC>GGA; CCA>CCC; TGC>TCC; 
GGT>GGC; TCT>ACT)
(n = 2)
- - - 1(50) 1(50) -
DISCUSSION
Based on subject characteristic, 
the numberof male patients wasmore 
than female patients with the ratio of 
2:1. This result wasin line with Lo et al.2 
research where male patients tends to 
be 2-3 times more than female patients. 
Sun D1mentioned that NPC incidence in 
male patients tends to be higher by 2.5-
2.6 times than female patients. In age 
characteristic, it found that the average 
of age was50.9. It wasshown that NPC 
occurrencemainly found in middle 
ages. Girri and Sarraf15 suggestedthat 
the peak of NPC occurrencewasin the 
50-59 of age. The unspecified symptoms 
of NPC (flu-like symptom, laryngitis or 
nasal inflammation in the early stage 
of cancer) isthe main reason why most 
of NPC patients come to hospital at 
late stage. This study showed thatmost 
patients (81.3%) at the stage IV of NPC 
while the stage I was only 3.1%. 
The most abundant LMP2A gene 
couldonly be amplified in cytobrush 
sample, whereas LMP2A was not 
expressed in peripheral blood sample 
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of NPC patients or control gene. It 
mightoccur because cytobrushwastaken 
from the site of cancer so the probability 
of captured EBV-infected B cell wasmuch 
higher than in peripheral blood samples. 
For NPC peripheral blood samples, the 
volume of blood wasonly 100 µL and 
900 µL lysis buffer. With only sucha 
small amount of blood volume, it 
contributesto the unamplified LMP2A 
gene because there are other types of 
cells in the blood sample. In addition, 
the possibilities werealso caused by very 
low concentration of DNA in peripheral 
blood than in cytobrush samples. Junker 
16said that so many years after acute 
infection of EBV, infected B cell and in 
latent phase in the peripheral blood 
accounts for more than 1-60 per 106 B 
cells (± 10 mL blood). Kieff17 mentioned 
that EBV that infects B cell is found in 
only 1 of a million B cells.
According to the result ofsequencing 
test from cytobrush samples, there was 
a change in gene sequence compared to 
wildtype (Gen Bank AJ 507799.2). It was 
also found another epitope besides CTL-
HLA-A24, named CTL-HLA-A2, so that the 
results need to be analyzed thoroughly.
From sequence analysis of LMP2A 
gene, it was found five nucleotide 
variations: the change of base sequence 
from GGC to GGA (C→A in position 
1350, GenBank AJ 507799.2), however, 
translated amino acid remained the same 
(Glycine, G). the second was the sequence 
change from CCA to CCC (A→C in position 
1374, GenBankAJ 507799.2), however, 
translated amino acid remained the same 
(Proline). The third was the sequence 
change from TGC to TCC (G→C in 
position 1375, GenBankAJ 507799.2) and 
transformed cystein to serine. The fourth 
was the sequence change from GGT to 
GGC (T→C in position 1392, GenBank AJ 
507799.2), however, translated amino 
acid remained the same (Glycine). The 
fifth was the sequence change from TCT 
to ACT (T→A in position 1438, GenBank 
AJ 507799.2) and transformed serine to 
threonine.
Cystein and serine are non-charged 
amino acid, so that the change from 
cystein to serin will not affect the 
whole polarity and charge of amino 
acid sequence. But another possibility 
emerges: it may cause the difference of 
binding action with HLA amino acids. 
The change of amino acid sequence 
may cause non optimal recognition 
of the CTL. Research conductedby 
Wiqoyah18 towards three epitopes from 
lymphoblastoid cell line from NPC 
patients found that there werechange 
of amino acid at epitope 8 from epitope 
TYGPVFMCL, epitope 1 from epitope 
CLGGLLTMV and epitope 6 from epitope 
SSCPLSKILL. The difference between 
our research and Wiqoyah’sisin type and 
samples amount.
Khanna et al.13 mentioned that 
the change of amino acid sequence 
in the anchor epitope CTL will cause 
nonbinding epitope with its HLA, so 
that CTL will not recognize HLA-epitope 
complex. In the other hand, the change 
of amino acid sequence in the part that 
binds T cell receptor (TCR) will cause 
CTL to recognize the epitope but not 
optimal.Ming Lung et al.19suggested 
that the expression of LMP2A in NPCis 
highly related to the evading mechanism 
of EBV against immune surveillance 
represented by CTL.
The 119 amino-terminalcytoplasmic 
domain of LMP2A coded from the 
first exon hold an important part in 
LMP2A function. In that part there is 
phosphorylation spot for tyrosine, serine 
and threonine as well asabinding spot for 
certainprotein kinases such astyrosine 
kinase from src family coded by Lyn 
and Fyn, which will later function in 
inhibiting B cell’s signal transduction 
by interacting with Lyn protein kinase. 
Tanaka et al.20 statedthat LMP2A is the 
specific target of CTL, so that the mutation 
of this target will cause disturbance in 
CTL response towards LMP2A causing 
rapid growth of cells in the host body. 
Moningka MEW, et al., Sequence variation of ...
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Serin amino acid change is reported to be 
the most common in NPC in China. This 
change is advantageous forthe EBV to be 
persistent in B cells. This also showed 
that LMP2A has an important rolethat 
causes EBV to be latent in the host.
We found five different variations in 
each sample which underwentreanalysis 
to see the distribution between those 
variations in all samples. The variations 
are: Type I: TCT>ACT (change in one 
nucleotide), Type II: GGC>GGA, CCA>CCC, 
TGC>TCC, GGT>GGC(change in four 
nucleotides) and Type III: GGC>GGA, 
CCA>CCC,TGC>TCC, GGT>GGC, TCT>ACT 
(change in five nucleotides).It can be 
suggested that Type I with a change in 
one nucleotide as many as 37.5%, Type II 
with four changes of nucleotide as many 
as eight samples (50%) and Type III with 
five changes of nucleotide as many as 
12.5% from all samples.
From the results above, it was 
obtained the relationship between 
sequence variation of LMP2A gene and 
tumourstagewhich are: In type I showed 
the same presentation between stage4a 
and 4c which was 50% each. In Type 
II, the presentation differed between 
stage3, 4a and 4b whereas the highest 
presentation was in stage 4b (62.5%). 
In Type III, it was also found the same 
presentation between stage4a and 4b 
which was 50% each. Compared to Type 
II and Type III, only in Type I (the change 
of nucleotide TCT>ACT) stage4c could be 
found. From these results, there was a 
association between sequence variation 
and tumorstage. Previous study showed 
thatdetected EBV in NPC case had a 
connection with its stage, whereas there 
was more positive EBVs in late cancer 
stage. LMP2A are important for the 
migration of the cell, its increase the 
metastasis progress. LMP2A mimicry 
BCR and activated Akt/Pkb from PI3K 
pathway, the function of pro apoptosis 
protein Bad and Glycogensintese kinase 
3β was inhibited. And its caused β catenin 
are not degradation, as we know β catenin 
play important role in cell differentiation 
and oncogenic transformation. Itwas 
also a E cadherin component that have 
function in adhesion of the cell.21
In our research, we found another 
variation compared the previous 
research conductedby Wiqoyah.18 The 
variation is in the upstream sequence of 
LMP2A from GGC>GGA which is silent 
mutation and the other variation is in 
downstream sequence of LMP2A from 
TCT>ACT which is missense mutation. 
It is assumed that those sequence 
variations might be affecting structure 
change of LMP2A amino acids, so that 
interaction between LMP2A and CTL 
epitope is not immunogenic enough to 
activated CTL, results in escape from 
immune surveillance. To prove this 
evidence, further study is needed.
CONCLUSION
It is concluded that cytobrush is still 
the best choice for screening or diagnosis 
of NPC. Moreover, the findingof five 
variations of LMP2A gene which are: 
the change of base sequence from GGC 
to GGA, from CCA to CCC, from TGC to 
TCC, from GGT to GGC, and from TCT to 
ACT. CCA>CCC and TGC>TCC variation 
are found on epitope TYGPVMCL which 
is recognized by HLA-A24 changes 
into TYGPVFMSL caused by missense 
mutation. Variation of CCA>CCC does 
not change the amino acid sequence 
thus does not alterepitope’s shape. 
Moreover, on epitope associated with 
HLA-A2 (CLGGLLTMV), there is a change 
of base sequence from GGT to GGC, 
however, this change does not transform 
translated amino acid, it is still glycine 
(silent mutation). In addition, the 
new variationsfound in the upstream 
sequence of LMP2A from GGC>GGA 
which is silent mutation and the other 
variation is in downstream sequence of 
LMP2A from TCT>ACT which is missense 
mutation. 
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